絞り込み

16645

広告

Vonoprazan-Based Triple-Therapy Could Improve Efficacy of the Tailored Therapy of Helicobacter pylori Infection.

著者 Shinmura T , Adachi K , Yamaguchi Y , Izawa S , Hijikata Y , Ebi M , Funaki Y , Ogasawara N , Sasaki M , Kasugai K
J Gastrointestin Liver Dis.2019 Dec 09 ; 28(4):389-395.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (20view , 0users)

Full Text Sources

The prevalence of clarithromycin resistant bacteria is increasing, and the effectiveness of Helicobacter pylori (H. pylori) triple therapy is gradually decreasing in Japan. Vonoprazan, a potassiumcompetitive acid blocker, has been reported for its effectiveness in eradicating H. pylori. We aimed to evaluate the efficacy of tailored vonoprazan-based triple therapy in patients with H. pylori. This study is the first to compare the efficacy of vonoprazan-based tailored triple therapy to that of vonoprazan-based conventional therapy.
PMID: 31826057 [PubMed - in process]
印刷用ページを開く Endnote用テキストダウンロード